Discover undervalued stocks with Eulerpool.

Subscribe for $2

Zoetis Stock ZTS

Price

146.50
Today +/-
-0.31
Today %
-0.25 %

Zoetis stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zoetis stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zoetis stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zoetis stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zoetis's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zoetis Stock Price History

DateZoetis Price
10/2/2025146.50 undefined
10/1/2025146.86 undefined
9/29/2025146.32 undefined
9/28/2025143.06 undefined
9/25/2025143.50 undefined
9/24/2025141.13 undefined
9/24/2025141.26 undefined
9/23/2025142.02 undefined
9/22/2025144.66 undefined
9/19/2025145.89 undefined
9/18/2025147.11 undefined
9/17/2025146.94 undefined
9/16/2025146.01 undefined
9/15/2025146.11 undefined
9/12/2025148.21 undefined
9/11/2025150.85 undefined
9/10/2025148.01 undefined
9/9/2025149.81 undefined
9/8/2025151.50 undefined
9/5/2025152.81 undefined
9/4/2025153.21 undefined
9/3/2025152.44 undefined

Zoetis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zoetis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zoetis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zoetis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zoetis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zoetis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zoetis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zoetis’s growth potential.

Zoetis Revenue, EBIT and net profit per share

DateZoetis RevenueZoetis EBITZoetis Net Income
2030e12.71 B undefined5.47 B undefined4.42 B undefined
2029e12.12 B undefined4.89 B undefined4.12 B undefined
2028e11.3 B undefined4.62 B undefined3.78 B undefined
2027e10.77 B undefined4.32 B undefined3.45 B undefined
2026e10.19 B undefined4.01 B undefined3.16 B undefined
2025e9.62 B undefined3.74 B undefined2.92 B undefined
20249.26 B undefined3.39 B undefined2.49 B undefined
20238.54 B undefined3.11 B undefined2.34 B undefined
20228.08 B undefined2.95 B undefined2.11 B undefined
20217.78 B undefined2.82 B undefined2.04 B undefined
20206.68 B undefined2.28 B undefined1.64 B undefined
20196.26 B undefined2.03 B undefined1.5 B undefined
20185.83 B undefined1.92 B undefined1.43 B undefined
20175.31 B undefined1.75 B undefined864 M undefined
20164.89 B undefined1.44 B undefined821 M undefined
20154.77 B undefined1.1 B undefined339 M undefined
20144.79 B undefined998 M undefined583 M undefined
20134.56 B undefined849 M undefined504 M undefined
20124.34 B undefined895 M undefined436 M undefined
20114.23 B undefined685 M undefined245 M undefined
20103.58 B undefined330 M undefined110 M undefined
20092.76 B undefined287 M undefined-100 M undefined

Zoetis Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
20092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
2.763.584.234.344.564.794.774.895.315.836.266.687.788.088.549.269.6210.1910.7711.312.1212.71
-29.7818.172.435.194.91-0.422.588.579.767.476.6316.493.915.748.333.905.925.694.957.264.84
62.8659.6961.1264.1863.9364.7964.0366.5366.7867.6768.4369.3670.6169.7370.4670.6868.0364.2360.7757.9053.9851.49
1.742.142.592.782.923.13.053.253.543.944.284.635.495.636.026.54000000
-0.10.110.250.440.50.580.340.820.861.431.51.642.042.112.342.492.923.163.453.784.124.42
--210.00122.7377.9615.6015.67-41.85142.185.2465.285.049.2024.363.7810.886.0617.468.159.379.508.917.28
----0.270.300.340.390.440.540.690.851.081.351.561.802.001.801.992.182.372.54
0000011.1113.3314.7112.8222.7327.7823.1925.8826.1715.5615.3811.11-1010.569.558.727.17
500500500500500.3502502498.2493.2486.9481.8478.6476.7470.4462.27454.85000000
- - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Zoetis Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zoetis is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (B)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
201020112012201320142015201620172018201920202021202220232024
                             
0.060.080.320.610.881.150.731.561.71.933.63.483.582.041.99
0.770.870.91.140.980.940.9111.041.091.011.131.221.31.32
000000000000000
11.061.351.291.291.471.51.431.391.411.631.922.352.562.31
285298302316314272248228271320368392369436379
2.122.312.863.363.473.833.394.224.44.756.616.937.516.345.99
1.151.241.241.31.321.311.381.441.662.132.392.62.973.443.62
000000000000000
000000000000000
0.920.930.870.80.731.191.231.272.051.891.711.471.381.341.13
0.930.990.990.980.981.461.481.512.522.592.692.682.752.762.72
162240304121102131169155155186200211320403781
3.173.43.43.23.124.084.264.376.386.876.977.427.948.25
5.285.716.266.566.597.917.658.5910.7811.5513.6113.914.9314.2914.24
                             
000555555555555
0000.880.961.011.021.011.031.041.071.071.091.131.18
-0.01-0.01-0.010.280.710.881.482.113.274.435.667.198.6710.311.97
3.363.734.03-0.22-0.36-0.62-0.6-0.51-0.63-0.73-0.73-0.76-0.82-0.84-0.94
000000000000000
3.343.724.030.941.311.271.912.623.674.7567.58.9410.5912.22
206214319506290293265261313301457436405411433
0.220.270.320.80.710.910.690.670.750.850.891.141.031.111.24
3423564119576173164165148151218218385361390
000000000040230
0.0400.070.020.010.41000.010.50.601.3501.35
0.810.841.121.421.091.781.121.091.221.812.171.83.171.893.41
0.670.580.513.643.624.464.474.956.445.956.66.596.556.575.23
218311323322277264244380474434378320142146167
241246266217264314321373452650693647661688661
1.131.131.14.184.175.045.035.717.377.037.677.567.367.416.06
1.941.982.225.65.256.826.156.88.598.849.849.3610.529.39.47
5.285.76.256.546.568.098.069.4212.2613.5915.8416.8519.4719.8921.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zoetis provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zoetis's financial health and stability.

Assets

Zoetis's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zoetis must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zoetis after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zoetis's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
200920102011201220132014201520162017201820192020202120222023
-0.10.110.250.440.50.590.340.820.861.421.51.642.032.112.34
124185205200209204199240242308412441448465491
-334-6865-7423-49-85-55127-112-79-62-80-286-61
357100-117-149-104-157-208-439-29112-151-85-343-699-512
67-58115699373462185188111180255212383155
037373160118117165167190247257253242295
264209142276134278224408455336418418548638754
0.10.250.50.450.680.630.660.711.351.791.82.132.211.912.35
-135-124-135-126-184-180-224-216-224-338-460-453-477-586-732
-1,821-9-449-135-179-187-1,115-214-270-2,259-504-572-458-883-777
-1,686115-314-95-7-8912-46-1,921-44-11919-297-45
000000000000000
0.720-0.1402.64-0.011.12-0.410.481.49-0.010.74-0.61.35-1.35
000002-192-275-476-679-619-230-778-1,632-1,065
1.82-0.28-0.03-0.08-0.2-0.150.76-0.9-0.250.53-0.950.12-1.86-0.9-3.11
1.1-0.280.11-0.08-2.74-00-0.04-0.05-0.04-0.01-0.01-0.01-0.01-0
0000-98-146-168-188-206-243-314-380-474-611-692
0.09-0.040.020.240.290.270.27-0.430.840.040.331.67-0.120.1-1.54
-371303623284974464404971,1221,4521,3351,6731,7361,3261,621
000000000000000

Zoetis stock margins

The Zoetis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zoetis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zoetis.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zoetis's sales revenue. A higher gross margin percentage indicates that the Zoetis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zoetis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zoetis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zoetis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zoetis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zoetis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zoetis Margin History

Zoetis Gross marginZoetis Profit marginZoetis EBIT marginZoetis Profit margin
2030e70.68 %43.04 %34.78 %
2029e70.68 %40.36 %33.99 %
2028e70.68 %40.91 %33.48 %
2027e70.68 %40.14 %32.09 %
2026e70.68 %39.37 %31.01 %
2025e70.68 %38.89 %30.37 %
202470.68 %36.66 %26.86 %
202370.46 %36.34 %27.43 %
202269.73 %36.51 %26.16 %
202170.61 %36.23 %26.2 %
202069.36 %34.1 %24.54 %
201968.43 %32.49 %23.96 %
201867.67 %33.03 %24.52 %
201766.78 %32.99 %16.28 %
201666.53 %29.4 %16.8 %
201564.03 %23.06 %7.11 %
201464.79 %20.86 %12.18 %
201363.93 %18.61 %11.05 %
201264.18 %20.64 %10.06 %
201161.12 %16.18 %5.79 %
201059.69 %9.21 %3.07 %
200962.86 %10.4 %-3.62 %

Zoetis Stock Sales Revenue, EBIT, Earnings per Share

The Zoetis earnings per share therefore indicates how much revenue Zoetis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zoetis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zoetis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zoetis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zoetis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zoetis Revenue, EBIT and net profit per share

DateZoetis Sales per ShareZoetis EBIT per shareZoetis Earnings per Share
2030e27.93 undefined0 undefined9.72 undefined
2029e26.64 undefined0 undefined9.06 undefined
2028e24.84 undefined0 undefined8.32 undefined
2027e23.67 undefined0 undefined7.59 undefined
2026e22.39 undefined0 undefined6.94 undefined
2025e21.14 undefined0 undefined6.42 undefined
202420.35 undefined7.46 undefined5.47 undefined
202318.48 undefined6.72 undefined5.07 undefined
202217.18 undefined6.27 undefined4.49 undefined
202116.31 undefined5.91 undefined4.27 undefined
202013.95 undefined4.76 undefined3.42 undefined
201912.99 undefined4.22 undefined3.11 undefined
201811.96 undefined3.95 undefined2.93 undefined
201710.76 undefined3.55 undefined1.75 undefined
20169.81 undefined2.88 undefined1.65 undefined
20159.49 undefined2.19 undefined0.68 undefined
20149.53 undefined1.99 undefined1.16 undefined
20139.12 undefined1.7 undefined1.01 undefined
20128.67 undefined1.79 undefined0.87 undefined
20118.47 undefined1.37 undefined0.49 undefined
20107.16 undefined0.66 undefined0.22 undefined
20095.52 undefined0.57 undefined-0.2 undefined

Zoetis business model

Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses. Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc. Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey. Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians. In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems. In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain. In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency. Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control. In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance. Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves. Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®). In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis is one of the most popular companies on Eulerpool.com.

Zoetis SWOT Analysis

Strengths

Zoetis Inc is a leading global animal health company, enjoying a strong market presence and brand reputation.

The company boasts a diverse portfolio of animal health products, including vaccines, diagnostics, and medicines.

Zoetis Inc has a highly skilled and experienced workforce, enabling efficient research and development processes.

Weaknesses

Zoetis Inc heavily relies on a few major customers, which poses a potential risk to its revenue if any customer reduces or discontinues their purchases.

The company faces high regulatory requirements and strict compliance standards in the animal health industry, which may increase operational costs.

Zoetis Inc has limited geographic diversification, with a significant portion of its revenue coming from sales in North America.

Opportunities

The growing global concern for animal welfare and the increasing demand for quality healthcare products provide an opportunity for Zoetis Inc to expand its product offerings.

The rise in pet ownership and the growing pet healthcare market offer potential for the company's growth.

The advancement of technology, such as digital platforms and data analytics, can enable Zoetis Inc to enhance its research capabilities and develop innovative solutions.

Threats

Zoetis Inc faces intense competition from both multinational corporations and local players in the animal health industry.

Changes in government regulations and policies can impact market access, pricing, and product approvals.

Economic downturns and fluctuations in currency exchange rates can affect the purchasing power and demand for animal health products.

Zoetis Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Contract Manufacturing and Human Health Diagnostics----
Companion Animal----
Livestock----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Companion Animal----
Livestock----
Animal health diagnostics----
Anti-infectives----
Medicated feed additives----
Other non-pharmaceuticals----
Other pharmaceuticals----
Parasiticides----
Total Products and Services----
Vaccines----
Dermatology----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Other----
Cattle----
Dogs and Cats----
Fish----
Horses----
Poultry----
Swine----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Animal health diagnostics----
Anti-infectives----
Dermatology----
Medicated feed additives----
Other non-pharmaceuticals----
Other pharmaceuticals----
Parasiticides----
Total Products and Services----
Vaccines----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Livestock3.04 B USD2.96 B USD3.1 B USD2.93 B USD
Companion Animal2.23 B USD1.76 B USD1.63 B USD1.63 B USD
Cattle1.74 B USD1.68 B USD1.75 B USD1.63 B USD
Dogs and Cats2.08 B USD1.59 B USD1.45 B USD1.45 B USD
Anti-infectives1.25 B USD1.31 B USD1.4 B USD1.3 B USD
Vaccines1.37 B USD1.15 B USD1.21 B USD1.2 B USD
Other pharmaceuticals1.18 B USD910 M USD783 M USD744 M USD
Parasiticides763 M USD651 M USD708 M USD727 M USD
Swine621 M USD668 M USD695 M USD655 M USD
Poultry479 M USD525 M USD568 M USD541 M USD
Medicated feed additives475 M USD505 M USD479 M USD446 M USD
Other non-pharmaceuticals218 M USD194 M USD155 M USD148 M USD
Horses151 M USD162 M USD182 M USD179 M USD
Other (Fish and Sheep)-85 M USD93 M USD104 M USD
Contract Manufacturing44 M USD51 M USD50 M USD-
Fish118 M USD---
Other84 M USD---
Contract Manufacturing and Human Health Diagnostics----

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Zoetis Revenue by Segment

Segmente2017201520142013
Reportable Segment--4.74 B USD4.56 B USD
United States Segment2.62 B USD---
International-2.39 B USD--
International Segment660 M USD---
Other business activities--50 M USD-

Zoetis Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Zoetis Revenue by Segment

DateAsia Pacific (APAC)AUSTRALIABRAZILCANADACanada and Latin AmericaCanada and Latin America (CLAR)CHILECHINAEurope, Africa, and Middle East (EuAfME)FRANCEGERMANYInternationalITALYJAPANMEXICOOther developed marketsOther emerging marketsSPAINTotal Geographical AreaUNITED KINGDOMUnited StatesUnited States (U.S.)
2023-323 M USD393 M USD255 M USD--140 M USD320 M USD-142 M USD202 M USD-121 M USD158 M USD162 M USD512 M USD784 M USD122 M USD8.47 B USD277 M USD4.56 B USD-
2022-289 M USD330 M USD238 M USD--141 M USD382 M USD-126 M USD176 M USD-111 M USD173 M USD136 M USD468 M USD758 M USD118 M USD7.99 B USD235 M USD4.31 B USD-
2021-259 M USD312 M USD232 M USD--136 M USD357 M USD-132 M USD183 M USD-115 M USD186 M USD133 M USD467 M USD778 M USD128 M USD7.69 B USD234 M USD4.04 B USD-
2020-207 M USD258 M USD210 M USD--100 M USD266 M USD-118 M USD159 M USD-90 M USD177 M USD116 M USD388 M USD656 M USD112 M USD6.59 B USD178 M USD3.56 B USD-
2019-196 M USD293 M USD206 M USD---200 M USD-117 M USD153 M USD-112 M USD158 M USD117 M USD370 M USD738 M USD114 M USD6.18 B USD198 M USD3.2 B USD-
2018-189 M USD295 M USD203 M USD---211 M USD-130 M USD147 M USD-104 M USD149 M USD100 M USD361 M USD710 M USD110 M USD5.77 B USD181 M USD2.88 B USD-
2016-----------2.39 B USD--------2.45 B USD-
2015-----------2.39 B USD--------2.33 B USD-
2014720 M USD---815 M USD---1.14 B USD------------2.06 B USD
2013713 M USD----778 M USD--1.17 B USD------------1.9 B USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zoetis Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zoetis historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zoetis shares outstanding

The number of shares was Zoetis in 2024 — This indicates how many shares 454.848 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zoetis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zoetis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zoetis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zoetis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zoetis dividend history and estimates

In 2024, Zoetis paid a dividend amounting to 1.8 undefined. Dividend means that Zoetis distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Zoetis provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Zoetis’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Zoetis's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Zoetis Dividend History

DateZoetis Dividend
2030e2.54 undefined
2029e2.37 undefined
2028e2.18 undefined
2027e1.99 undefined
2026e1.8 undefined
2025e1 undefined
2025e1 undefined
20241.8 undefined
20231.56 undefined
20221.35 undefined
20211.08 undefined
20200.85 undefined
20190.69 undefined
20180.54 undefined
20170.44 undefined
20160.39 undefined
20150.34 undefined
20140.3 undefined
20130.27 undefined

Zoetis dividend payout ratio

In 2024, Zoetis had a payout ratio of 25.88%. The payout ratio indicates the percentage of the company's profits that Zoetis distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Zoetis represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Zoetis could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Zoetis's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Zoetis Payout Ratio History

DateZoetis Payout ratio
2030e26.19 %
2029e26.13 %
2028e26.27 %
2027e26.17 %
2026e25.94 %
2025e26.69 %
202425.88 %
202325.25 %
202228.95 %
202123.42 %
202023.39 %
201921.09 %
201817.2 %
201724 %
201623.03 %
201548.82 %
201424.83 %
201319.31 %
201225.25 %
201125.25 %
201025.25 %
200925.25 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Zoetis.

Zoetis latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20251.63 1.76  (7.75 %)2025 Q2
3/31/20251.41 1.48  (5.17 %)2025 Q1
12/31/20241.35 1.4  (3.63 %)2024 Q4
9/30/20241.47 1.58  (7.51 %)2024 Q3
6/30/20241.5 1.56  (3.91 %)2024 Q2
3/31/20241.35 1.38  (2.28 %)2024 Q1
12/31/20231.33 1.24  (-6.94 %)2023 Q4
9/30/20231.37 1.36  (-0.91 %)2023 Q3
6/30/20231.33 1.41  (6.13 %)2023 Q2
3/31/20231.27 1.31  (2.86 %)2023 Q1
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Zoetis stock

Eulerpool World ESG Rating (EESG©)

87/ 100

🌱 Environment

97

👫 Social

99

🏛️ Governance

66

Environment

Scope 1 - Direct Emissions
111,637
Scope 2 - Indirect emissions from purchased energy
177,750
Scope 3 - Indirect emissions within the value chain
72,668
Total CO₂ emissions
289,387
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees48
Percentage of women in management
Percentage of Asian employees11.1
Share of Asian management10.57
Percentage of Hispanic/Latino employees6.9
Hispano/Latino Management share4.53
Percentage of Black employees4.6
Black Management Share3.62
Percentage of white employees74.8
White Management Share80.06
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Zoetis shareholders

%
Name
Stocks
Change
Date
9.16497 % The Vanguard Group, Inc.41,686,702326,6956/30/2025
4.98087 % BlackRock Institutional Trust Company, N.A.22,655,386-498,1256/30/2025
4.33936 % State Street Global Advisors (US)19,737,484-59,3076/30/2025
3.70321 % State Farm Insurance Companies16,843,994-34,1006/30/2025
2.43626 % Geode Capital Management, L.L.C.11,081,30195,2946/30/2025
1.95443 % Wellington Management Company, LLP8,889,6802,824,3056/30/2025
1.85139 % Polen Capital Management, LLC8,421,026-375,8216/30/2025
1.48490 % Morgan Stanley Investment Management Ltd. (UK)6,754,0204,575,0366/30/2025
1.28236 % Wells Fargo Advisors5,832,810-180,3776/30/2025
1.14120 % Norges Bank Investment Management (NBIM)5,190,711131,3566/30/2025
1
2
3
4
5
...
10

Zoetis Executives and Management Board

Ms. Kristin Peck

(52)
Zoetis Chief Executive Officer, Director (since 2012)
Compensation 15.24 M

Mr. Wetteny Joseph

(51)
Zoetis Chief Financial Officer, Executive Vice President
Compensation 4.25 M

Mr. Robert Polzer

(55)
Zoetis Executive Vice President, President - Research and Development
Compensation 2.44 M

Mr. Michael Mccallister

(71)
Zoetis Non-Executive Independent Chairman of the Board
Compensation 490,000

Ms. Louise Parent

(73)
Zoetis Independent Director
Compensation 370,000
1
2
3
4
...
5

Zoetis Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
PetMed Express, Inc. Stock
PetMed Express, Inc.
SupplierCustomer0,670,780,880,560,29-0,54
Model N, Inc. Stock
Model N, Inc.
SupplierCustomer0,590,860,680,850,36-0,50
Quanterix Corporation Stock
Quanterix Corporation
SupplierCustomer0,550,880,930,960,42
CryoPort Stock
CryoPort
SupplierCustomer0,530,460,880,940,650,38
Petco Health and Wellness Company A Stock
Petco Health and Wellness Company A
SupplierCustomer0,510,680,470,190,24
Pfizer Stock
Pfizer
SupplierCustomer0,480,920,100,390,080,73
ID Logistics Group SA Stock
ID Logistics Group SA
SupplierCustomer0,470,720,500,730,360,81
Enero Group Stock
Enero Group
SupplierCustomer0,410,790,680,710,400,75
Optipharm Stock
Optipharm
SupplierCustomer0,310,610,730,420,04
LiveWorld, Inc. Stock
LiveWorld, Inc.
SupplierCustomer0,210,430,19-0,67-0,51
1
2

Most common questions regarding Zoetis

What values and corporate philosophy does Zoetis represent?

Zoetis Inc represents a strong set of values and corporate philosophy. As a global animal health company, Zoetis Inc is committed to improving the health and well-being of animals by providing innovative products and services. With a focus on sustainability, they strive to make a positive impact on the world we live in. Zoetis Inc values integrity, accountability, collaboration, and customer focus. Their dedication to research and development ensures the delivery of high-quality solutions for animal health. By constantly evolving and embracing technological advancements, Zoetis Inc remains at the forefront of the industry, dedicated to improving the lives of animals, the people who care for them, and the communities they serve.

In which countries and regions is Zoetis primarily present?

Zoetis Inc., a leading animal health company, operates in various countries and regions worldwide. With a strong global presence, Zoetis primarily serves customers in North America, Europe, Africa, Asia, and Latin America. The company's extensive network allows it to deliver innovative animal health solutions and support to a diverse range of customers across these regions. Zoetis' commitment to expanding its reach and impact in the animal health industry is reflected in its presence and operations throughout these key locations.

What significant milestones has the company Zoetis achieved?

Zoetis Inc., a leading animal health company, has achieved several significant milestones in its history. Since its establishment in 2013 as a spin-off from Pfizer, Zoetis has continuously strived for innovation and growth. Some noteworthy milestones include its successful initial public offering (IPO) in 2013, becoming the largest animal health IPO in history. The company has also established itself as a global leader in animal health, expanding its presence in various markets worldwide. Additionally, Zoetis has consistently focused on research and development, introducing innovative products and solutions to address the health and well-being of animals. Through its dedication and expertise, Zoetis Inc. continues to make remarkable progress in the animal health industry.

What is the history and background of the company Zoetis?

Zoetis Inc is a leading global animal health company that specializes in the discovery, development, manufacture, and commercialization of a wide range of veterinary medicines and vaccines. Founded in 1952, Zoetis has a rich history of providing innovative solutions to improve the health and well-being of animals. With a strong commitment to research and development, the company has introduced numerous cutting-edge products and technologies that have revolutionized the field of animal health. Zoetis operates in more than 100 countries, serving veterinarians, livestock producers, and pet owners worldwide. This dedication to delivering high-quality, safe, and effective animal healthcare solutions has established Zoetis as a trusted name in the industry.

Who are the main competitors of Zoetis in the market?

The main competitors of Zoetis Inc in the market are Merck & Co Inc, Elanco Animal Health Inc, and Boehringer Ingelheim GmbH.

In which industries is Zoetis primarily active?

Zoetis Inc primarily operates in the animal health industry.

What is the business model of Zoetis?

Zoetis Inc. operates as a leading animal health company globally. The business model of Zoetis Inc. revolves around discovering, developing, manufacturing, and marketing a diverse range of animal health products and vaccines. With a focus on improving the health and well-being of animals, Zoetis aims to provide innovative solutions that enhance the health, productivity, and performance of livestock and companion animals. By offering a wide portfolio of products and services, Zoetis caters to the needs of veterinarians, livestock producers, and pet owners, thereby contributing to the overall welfare and sustainability of the animal health industry.

What is the P/E ratio of Zoetis 2025?

The Zoetis P/E ratio is 22.81.

What is the P/S ratio of Zoetis 2025?

The Zoetis P/S ratio is 6.93.

What is the Quality Investing of Zoetis?

The Quality Investing for Zoetis is 9/10.

What is the revenue of Zoetis 2025?

The expected Zoetis revenue is 9.62 B USD.

How high is the profit of Zoetis 2025?

The expected Zoetis profit is 2.92 B USD.

What is the business model of Zoetis

Zoetis Inc is a leading company in the animal health industry that focuses on the development, manufacturing, and marketing of pharmaceuticals, vaccines, and diagnostic tests for animals. The company was founded in 1952 and is based in Parsippany, New Jersey. Zoetis operates in various segments including cattle production, swine production, poultry research and diagnostics, small animal practice, equine and livestock practice, and ectoparasiticides. The company offers several products that appeal to veterinarians and farmers. In the cattle range, Zoetis offers products such as EXCEDE, an injection that ensures sustained efficacy against pathogens in cattle, DRAXXIN, an injectable antibiotic for treating cattle with respiratory diseases and BRD, and LUTALYSE, a hormone that helps cattle breeders and livestock dealers during calving. In the swine production area, Zoetis offers products such as RESFLOR GOLD, a combination of antibiotics used for treating respiratory diseases, FOSTERA, a vaccine that provides immunity against Porcine Reproductive and Respiratory Syndrome (PRRS) and facilitates the approval of PRRS-infected swine, and DRAXXIN, a treatment for swine with respiratory disease. Zoetis is also involved in poultry research and diagnostics. Products such as FLOKILL, a medication for treating coccidiosis in chickens, Amprol, a medication for treating coccidiosis in chickens, Zeppelin, a test kit for identifying salmonella in poultry, and Bio-Chr, a feed additive that increases egg production in laying hens. In the small animal practice, Zoetis offers products such as Simparica, a medication for parasites like ticks and fleas in dogs, and Revolution and Proheart, both medications for parasites in dogs and cats. Zoetis also offers products for horses and livestock, including EQUIOXX, an anti-inflammatory for horses with arthritis and kissing spine, and CONVENIA, an antibiotic for horses, cows, and sheep. Zoetis is not only involved in the development and marketing of animal pharmaceuticals, but also in educating animal owners and farmers. They provide resources and training for animal health and care, and provide research data and information to animal owners. Zoetis' business model is to provide animal owners and farmers with innovative products and services that improve animal health and help keep animals healthy. The company specializes in developing and offering safe and effective products for animals used in food production to secure the food supply. Overall, Zoetis has a strong position in the animal pharmaceutical and diagnostic sector. The company aims to make a positive contribution to animals and animal owners through innovative products and close collaboration with animal owners.

What is the Zoetis dividend?

Zoetis pays a dividend of 1.3 USD distributed over 4 payouts per year.

How often does Zoetis pay dividends?

Zoetis pays out a dividend 4 times a year.

What is the Zoetis ISIN?

The ISIN of Zoetis is US98978V1035.

What is the Zoetis WKN?

The WKN of Zoetis is A1KBYX.

What is the Zoetis ticker?

The ticker of Zoetis is ZTS.

How much dividend does Zoetis pay?

Over the past 12 months, Zoetis paid a dividend of 1.8 USD . This corresponds to a dividend yield of about 1.23 %. For the coming 12 months, Zoetis is expected to pay a dividend of 1.8 USD.

What is the dividend yield of Zoetis?

The current dividend yield of Zoetis is 1.23 %.

When does Zoetis pay dividends?

Zoetis pays a quarterly dividend. This is distributed in the months of November, February, May, August.

How secure is the dividend of Zoetis?

Zoetis paid dividends every year for the past 18 years.

What is the dividend of Zoetis?

For the upcoming 12 months, dividends amounting to 1.8 USD are expected. This corresponds to a dividend yield of 1.23 %.

In which sector is Zoetis located?

Zoetis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zoetis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zoetis from 9/3/2025 amounting to 0.5 USD, you needed to have the stock in your portfolio before the ex-date on 7/18/2025.

When did Zoetis pay the last dividend?

The last dividend was paid out on 9/3/2025.

What was the dividend of Zoetis in the year 2024?

In the year 2024, Zoetis distributed 1.557 USD as dividends.

In which currency does Zoetis pay out the dividend?

The dividends of Zoetis are distributed in USD.

All fundamentals about Zoetis

Our stock analysis for Zoetis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zoetis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.